Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Concordance of <i>EGFR</i> and <i>KRAS</i> mutation status between primary non–small cell lung cancer and corresponding metastases: A systematic review and meta-analysis.

Rahul Falodia, Shankar Biswas, Elangovan Krishnan et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20563

e20563 Background: Accurate molecular profiling is critical for NSCLC treatment selection. Metastatic tissue is frequently...

Longitudinal associations between patient and caregiver quality of life following hematopoietic stem cell transplantation.

Daniel Yang, Jesse D. Troy, Brenda Branchaud et al. Jun 01, 2026 pp. 12087-12087 10.1200/jco.2026.44.16_suppl.12087

12087 Background: Caregivers of patients undergoing hematopoietic stem cell transplantation (HSCT) experience high rates o...

Comparative safety and efficacy of obinutuzumab versus rituximab in combination with chemotherapy for follicular lymphoma: A systematic review and meta-analysis.

Abdul Rafae Faisal, Rana Uzair Ahmad, Muhammad Huzaifa Ahmed Khan et al. Jun 01, 2026 pp. 7068-7068 10.1200/jco.2026.44.16_suppl.7068

7068 Background: Follicular lymphoma is one of the most common non-Hodgkin lymphoma subtypes, typically presenting with ad...

Phase I/II study of LB1410, a bivalent TIM-3/PD-1 bispecific antibody, in combination with LB4330, a long-acting IL-10, in patients with advanced solid tumors.

Jiajian Liu, Jianming Guo, Xinan Sheng et al. Jun 01, 2026 pp. 2626-2626 10.1200/jco.2026.44.16_suppl.2626

2626 Background: LB1410 is an anti-PD-1/TIM-3 bispecific antibody (BsAb) developed by L&amp;L Bio Co., Ltd., Shanghai, Chi...

A phase Ib, open-label, clinical trial of JAB21822 combined with second-line chemotherapy for metastatic colorectal cancer with <i>KRAS</i> G12C mutation.

Zhenghang Wang, Wenhua Li, Sai Ge et al. Jun 01, 2026 pp. 3544-3544 10.1200/jco.2026.44.16_suppl.3544

3544 Background: Glecirasib (JAB-21822), a novel, covalent, small molecule KRAS G12C-GDP covalent inhibitor, has been show...

Predictivity of coagulation markers in diagnosing acute promyelocytic leukemia.

Mina Zheng, Changtai Tian, Luke Zhao Li et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18544

e18544 Background: Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia (AML) characterized...

Making telehealth delivery of cancer care at home effective and safe: A pragmatic cluster randomized trial.

Erin Mary Bange, Charlotte Diane Malling, Katherine Marcinkowski et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps1680

TPS1680 Background: Telehealth (TH) use for cancer care has rapidly expanded, both during and following the COVID-19 pande...

Distinct multi-omic signatures that underlie <i>KRAS</i> variants and survival in <i>KRAS</i> G12R pancreatic cancer.

Sargis Hovhannisyan, Aditi Bhargava, Jennifer Van Eyk et al. Jun 01, 2026 pp. 4234-4234 10.1200/jco.2026.44.16_suppl.4234

4234 Background: KRAS mutations are the dominant oncogenic drivers of pancreatic ductal adenocarcinoma (PDAC). While KRAS...

Timing and prognostic impact of thromboembolic events in lung cancer patients treated with immune checkpoint inhibitors: A time-dependent real-world analysis.

Chinemerem MARTLIN Emeasoba, Kevin Zhao, Samantha Robinson et al. Jun 01, 2026 pp. 11124-11124 10.1200/jco.2026.44.16_suppl.11124

11124 Background: Thromboembolic events (TEEs) are complications associated with malignancy, and emerging evidence suggest...

Age-stratified outcomes and racial disparities in hospitalized patients with endometrial cancer: A national analysis.

Ameerdad Khan, Srijani Thannir, Kameswara Santosh Dheeraj Nalluri et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17648

e17648 Background: The incidence of endometrial cancer is increasing in both younger and older populations, yet national a...

Impact of recent chemotherapy exposure on overall survival in patients with diffuse large B-cell lymphoma receiving bispecific antibody therapy.

Rafik ElBeblawy, Mariah Black, Mostafa Eysha et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e19093

e19093 Background: Diffuse large B-cell lymphoma (DLBCL) is cured with first-line chemoimmunotherapy, yet nearly 40% of pa...

CONVERGE-01 part 3: Ac-225 rosopatamab tetraxetan (CONV01-α) in Lu-PSMA-pretreated metastatic castration-resistant prostate cancer (mCRPC).

Michael J. Morris, Daniel J. George, Shilpa Gupta et al. Jun 01, 2026 pp. 5011-5011 10.1200/jco.2026.44.16_suppl.5011

5011 Background: Ac-225 rosopatamab tetraxetan (CONV01-α, Convergent Therapeutics, Cambridge, MA), an alpha-emitting radio...

Fatal infection–associated adverse events with B-cell maturation antigen–directed therapies in multiple myeloma: A FAERS pharmacovigilance study.

Valerin Arno, Aqsa Zoey Sorathia, Canan Dilay Dirican et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e19552

e19552 Background: B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapies and bispecif...

Variations in postoperative patient-reported outcomes (PROs) attributed to patients, surgeons, or surgical centers.

Roshan Paudel, Hajime Uno, Christine M. Cronin et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23277

e23277 Background: Postoperative PROs reflect patients’ subjective experiences and are influenced by numerous factors, inc...

Phase 1 first-in-human trial of AG01, a recombinant humanized monoclonal antibody to progranulin/glycoprotein 88 (GP88) to determine the safety, tolerability, pharmacokinetics, and preliminary antitumor activity in subjects with advanced solid tumor malignancies.

Katherine H.R. Tkaczuk, Katherine Ann Scilla, Gautam G. Rao et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps2669

TPS2669 Background: Progranulin also called GP88/PGRN plays a major role as an autocrine growth &amp; survival factor asso...

Genetic testing in endometrial cancer (GenEC): A study on the patient experience with MSK-IMPACT.

Christina Curtin, Nancy Varice, Varshini Gali et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22635

e22635 Background: Guidelines recommend consideration of genetic testing (GT) for patients with endometrial cancer (EC); h...

Differences in the receipt of recommended cardiovascular assessment among cancer survivors in the United States by atherosclerotic cardiovascular disease status.

Reed Mszar, Ash Blythe Alpert, Eunate Gallardo-Vara et al. Jun 01, 2026 pp. 12027-12027 10.1200/jco.2026.44.16_suppl.12027

12027 Background: Cardio-oncology guidelines recommend annual cardiovascular (CV) assessment among cancer survivors, parti...

Patterns of prostate-specific antigen levels for early detection of prostate cancer in sub-Saharan Africa.

Ayodeji Oluwatobi Ojetunde, Moyinoluwa Opeyemi Akinwumi, Janet Tijani et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22501

e22501 Background: Prostate cancer remains a major cause of morbidity and mortality among men in sub-Saharan Africa, large...

Spatial multi-omics profiling of the primary lung microenvironment to elucidate the mechanism of osseous metastasis in advanced NSCLC through imaging mass cytometry.

Luyun Cui, Yinan Yao, Xiang Tong et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20546

e20546 Background: Non-small cell lung cancer (NSCLC) is one of the world's deadliest cancers, including lung adenocarcino...

Examining the impact of community, knowledge, and shared support on the <i>EGFR</i> -mutated lung cancer care journey: Results from the first annual EGFR Resisters Patient and Caregiver Summit.

Bryan Carson Taylor, Jill Libles Feldman, Laura A. Petrillo et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13781

e13781 Background: Social isolation, loneliness, and lack of shared support networks are associated with increased psychos...

Oncological safety of oncoplastic breast conservation surgery: Experience of over a decade in early and locally advanced breast cancer from a tertiary care cancer center in India.

Shalaka Prakash Joshi, Ankita Nirpharake, Dushyant Jaiswal et al. Jun 01, 2026 pp. 584-584 10.1200/jco.2026.44.16_suppl.584

584 Background: Oncoplastic breast conservation surgery (O-BCS) is the norm. O-BCS improves cosmetic outcomes by restoring...

Blinded comparison of natural killer cell detection with AI-driven nanophotonic imaging versus traditional spectral flow cytometry: Development of the CB-Scout assay.

Rebecca Turk MacLeod, Joel Robert Eisner, Nima Sarshar et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e14539

e14539 Background: Chimeric antigen receptor natural killer (CAR-NK) cells and in vivo CAR-T therapies are emerging as pro...

ZIP-code–level distress as a predictor for advanced stage and mortality in female breast cancer across a multiethnic cohort in Hawaiʻi.

Chalothorn Wannaphut, Jodi A. Kagihara, Brenda Y. Hernandez et al. Jun 01, 2026 pp. 1649-1649 10.1200/jco.2026.44.16_suppl.1649

1649 Background: Native Hawaiian and Pacific Islander (NHPI) patients experience worse breast cancer outcomes; however, th...

Recurrence patterns and survival in hormone receptor-positive/HER2-negative early breast cancer: A retrospective analysis from a public oncologic institution in Peru.

Guillermo Valencia, Alexandra Saavedra, Zaida Morante et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23402

e23402 Background: Patients (pts) with hormone receptor (HR)-positive/HER2-negative early breast cancer (EBC) face a conti...

Feasibility and preliminary efficacy of a 12-week remotely delivered exercise program in patients receiving immunotherapy: A phase II randomized controlled trial.

Paulo Gustavo Bergerot, Cristiane Decat Bergerot, Jonas Ribeiro Gomes Silva et al. Jun 01, 2026 pp. 1638-1638 10.1200/jco.2026.44.16_suppl.1638

1638 Background: Patients with advanced cancer receiving immunotherapy experience reduced physical function, increased sym...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page